Tikosyn shortage resolved
Pfizer is reporting that the temporary Tikosyn (dofetilide) shortage has been resolved and that all dosage strengths (0.125mg, 0.25mg, and 0.5mg) are once again available. The product outage was due to an unforeseen manufacturing issue coupled with distribution regulations for Tikosyn, and was not the result of any efficacy or safety concern with Tikosyn. Tikosyn is indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of >1 week and for the conversion of atrial fibrillation/atrial flutter to normal sinus rhythm.
For more information call (800) 438-1985 or visit www.tikosyn.com.